Results 221 to 230 of about 41,565 (267)

Rituximab for relapsing-remitting multiple sclerosis

2011
More than 80% of individuals with multiple sclerosis (MS) experience a relapsing-remitting disease course. Approximately ten years after disease onset, an estimated 50% of individuals with relapsing-remitting MS (RR-MS) convert to secondary progressive MS. Quality of life is considerably impaired in early RR-MS.
Dian, He, Hongyu, Zhou, Wenjie, Han, Shihong, Zhang   +3 more
openaire   +2 more sources

Ibudilast in relapsing-remitting multiple sclerosis

Neurology, 2010
Ibudilast is a phosphodiesterase inhibitor influencing inflammation and neurodegeneration in multiple sclerosis (MS). This study evaluated the safety, tolerability, and effects on MRI parameters of 2 different doses of ibudilast in relapsing forms of MS.In this multicenter, double-blind, phase 2 trial, patients with relapsing MS and gadolinium ...
Barkhof, F., Hulst, H.E., Drulovic, J., Uitdehaag, B.M.J., Matsuda, K., Landin, R.   +5 more
openaire   +2 more sources

Daclizumab for relapsing remitting multiple sclerosis

2009
The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. Moreover, there are no severe safety concerns arising from clinical testing so far.To assess the efficacy and safety of daclizumab for patients with relapsing remitting multiple sclerosis.We ...
Jia, Liu, Luning, Wang, Siyan, Zhan, Jiping, Tan, Yinyin, Xia   +4 more
openaire   +2 more sources

Immunologic therapy for relapsing-remitting multiple sclerosis

Current Neurology and Neuroscience Reports, 2001
The treatment of relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis, has been revolutionized in recent years. In addition to effective treatment of acute relapses, therapies are now available to prevent relapses, reduce the burden of disease as seen on magnetic resonance imaging, and possibly even slow the course ...
H J, MacLean, M S, Freedman
openaire   +2 more sources

Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis

Expert Review of Neurotherapeutics, 2016
Despite recent advances in pharmacological management, multiple sclerosis (MS), an autoimmune disease of the central nervous system, remains a leading cause of disability. In relapsing-remitting (RR)MS, neurologists most commonly utilize immunomodulatory or immunosuppressive agents to benefit their patients.
Til, Menge, Divyanshu, Dubey, Clemens, Warnke, Hans-Peter, Hartung, Olaf, Stüve   +4 more
openaire   +2 more sources

[Relapsing-Remitting Multiple Sclerosis].

Brain and nerve = Shinkei kenkyu no shinpo, 2021
Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system. There are neither diagnostic tests nor markers for MS. Other causes must be excluded thoroughly before an MS diagnosis is considered definitive. The relapsing-remitting type is a major clinical course in MS. Most disease-modifying drugs (DMDs)
Masaaki, Niino, Yusei, Miyazaki
openaire   +1 more source

Executive functions in relapsing-remitting multiple sclerosis

Applied Neuropsychology: Adult, 2023
Some studies suggest that patients with relapsing-remitting multiple sclerosis have problems in the functioning of working memory, and more specifically in executive functions, but the available results are still inconsistent. The aim of the present study was to examine executive functioning in multiple sclerosis using classical and representative ...
M. Rosa Elosúa, Noelia Villadangos
openaire   +2 more sources

Natalizumab in relapsing-remitting multiple sclerosis

Expert Review of Neurotherapeutics, 2016
Natalizumab is the first humanized moclonal antibody indicated in the treatment of relapsing-remitting multiple sclerosis (RRMS). Based on its remarkable efficacy in reducing disease activity and reducing the risk of disability progession in RRMS, and the risk of a serious adverse event (progressive multifocal leukoencephalopathy [PML]), natalizumab ...
openaire   +2 more sources

Oral fumarate for relapsing-remitting multiple sclerosis

The Lancet, 2008
Udgivelsesdato: 2008/10 ...
Sorensen, P.S., Sellebjerg, F.
openaire   +2 more sources

Relapsing-Remitting Multiple Sclerosis

BioDrugs, 2000
Multiple sclerosis is now a treatable disease and several immunomodulating therapies exist, but their clinical efficacy is moderate and treatment failure during the course of the disease is an increasing problem. As agents with different targets are available, the question was raised whether combination of these therapies would: be safe;result in ...
M, Mäurer, P, Rieckmann
openaire   +2 more sources